Next Article in Journal
The Association between Methionine Intake and Diabetes in Chinese Adults—Results from the China Health and Nutrition Survey
Previous Article in Journal
Bioactive Substances of Potato Juice Reveal Synergy in Cytotoxic Activity against Cancer Cells of Digestive System Studied In Vitro
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 15
Issue 1
10.3390/nu15010113
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Trajectories of the Prevalence of Sarcopenia in the Pre- and Post-Stroke Periods: A Systematic Review

by
Tatsuro Inoue
1,
Junko Ueshima
2,
Fumiya Kawase
3,
Haruko Kobayashi
4,
Ayano Nagano
5,
Kenta Murotani
6,
Yoko Saino
7 and
Keisuke Maeda
8,*
1
Department of Physical Therapy, Niigata University of Health and Welfare, Niigata 950-3198, Japan
2
Department of Nutrition Service, NTT Medical Center Tokyo, Tokyo 141-8625, Japan
3
Department of Nutrition, Asuke Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Aichi 444-2351, Japan
4
General Incorporated Association Manabi Public Library, Aichi 465-0015, Japan
5
Department of Nursing, Nishinomiya Kyoritsu Neurosurgical Hospital, Hyogo 663-8211, Japan
6
Biostatistics Center, Kurume University, Fukuoka 830-0011, Japan
7
Department of Clinical Nutrition, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
8
Department of Geriatric Medicine, Hospital, National Center for Geriatrics and Gerontology, Aichi 474-8511, Japan
*
Author to whom correspondence should be addressed.
Nutrients 2023, 15(1), 113; https://doi.org/10.3390/nu15010113
Submission received: 1 December 2022 / Revised: 20 December 2022 / Accepted: 22 December 2022 / Published: 26 December 2022
(This article belongs to the Section Geriatric Nutrition)
Browse Figures
Review Reports Versions Notes

Abstract

:
Interventions for stroke-related sarcopenia in patients with stroke are needed, but the details of the target population are unclear. This systematic review aimed to identify trajectories of the prevalence of sarcopenia in the pre- and post-stroke periods and to determine the diagnostic criteria used in patients with stroke. We searched for literature in six databases: MEDLINE, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, CINAHL, and Ichushi-web (in Japanese). We included 1627 studies in the primary screening, and 35 studies were finally included. Of the 35 studies, 32 (91.4%) included Asian patients, and the criteria of the Asian Working Group for Sarcopenia was mainly used as the diagnostic criteria. Nineteen studies used muscle strength and muscle mass to diagnose sarcopenia, whereas a full assessment, including physical performance, was performed in five studies. The estimated prevalences of sarcopenia in pre-stroke, within 10 days of stroke, and from 10 days to 1 month after stroke were 15.8%, 29.5%, and 51.6%, respectively. Sarcopenia increased by approximately 15% from pre-stroke to 10 days, and increased by approximately 20% from 10 days to 1 month. Healthcare providers should note that the prevalence of sarcopenia increases during the acute phase in patients with stroke.

1. Introduction

Sarcopenia is an age-related skeletal muscle disease that is characterized by a loss of skeletal muscle mass, muscle strength, and physical performance [1]. Sarcopenia is a risk factor for disability, hospitalization, and death [1]. In 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) defined sarcopenia as the loss of skeletal muscle mass, muscle weakness, and physical function [2], leading to a notable increase in sarcopenia research. In 2014, the Asian Working Group for Sarcopenia (AWGS) published cutoff values of low skeletal muscle mass and muscle strength and physical performance for Asian populations [3]. Subsequently, the updated versions of the EWGSOP [4] and AWGS [5] algorithms were published. Research on sarcopenia has increased dramatically since the definitions of sarcopenia were established.
Sarcopenia is caused not only by aging, but also by multiple factors including nutrition, activity, and disease [1]. Nutritional causes of sarcopenia include insufficient protein and energy intake, micronutrient deficiency, malabsorption, and anorexia [1], while causes that relate to low activity levels include bed rest, inactivity, and decreased physical activity. Diseases that cause sarcopenia include bone and joint diseases, as well as chronic and neurological diseases [1]. In addition, hospital admission itself has been proposed as a iatrogenic cause of sarcopenia [1]. It has been reported that approximately 15% of patients develop new onset sarcopenia during hospitalization in acute care hospitals [6]. Patients hospitalized for disease treatment are more likely to develop sarcopenia and to develop severe sarcopenia due to causes such as malnutrition, low activity levels, and disease. Lack of awareness of sarcopenia among health care providers can lead to insufficient energy intake to meet the increased energy requirements caused by inflammation due to disease and surgical invasions; this accelerates the development of iatrogenic sarcopenia.
Globally, stroke is a primary disease, causing death and disability [7], and stroke patients are rapidly aging in recent years [8]. In Japan, which has the most aged population in the world, the mean age of stroke onset has increased during the past 20 years [8]. More than 70% of patients with stroke suffered long-term disability, and increasing age is more likely to result in an unfavorable outcome [9]. Therefore, it is essential for medical professionals to take a geriatric perspective in the treatment of stroke patients.
“Stroke-related sarcopenia” is a concept that indicates the onset or severity of sarcopenia due to stroke [10]. Stroke patients are more likely to develop or become severely sarcopenic due to the atrophy associated with paralysis and disuse, spasticity, inflammation, denervation, reinnervation, impaired feeding, and intestinal absorption [10,11]. Sarcopenia negatively affects clinical outcomes in patients with stroke. The prevalence of sarcopenia in stroke patients in acute hospitals has been reported to be 8.5–33.8% [12,13,14,15,16], and sarcopenia leads to unfavorable outcomes 90 days after stroke [15]. In post-acute rehabilitation hospitals, approximately 50% of patients suffer from sarcopenia on admission [17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32], and sarcopenia inhibits functional recovery and return to home in patients with stroke [25]. In addition, in several studies, pre-stroke sarcopenia was diagnosed using the SARC-F questionnaire [33,34,35,36], and pre-stroke sarcopenia was a predictor of functional outcome after 3 months [34]. Thus, sarcopenia in pre-stroke and stroke patients has a negative impact on clinical outcomes.
Interventions for stroke-related sarcopenia are needed, but details on the size of the target patient population are unclear. Identifying the trajectory of the prevalence of sarcopenia in stroke patients should clarify the number of potential patients requiring intervention and related healthcare costs. In addition, summarizing relevant criteria can help in standardizing the diagnosis of sarcopenia. This systematic review aimed to identify the trajectories of the prevalence of sarcopenia in the pre- and post-stroke periods and to determine the diagnostic criteria used in stroke patients.

2. Materials and Methods

2.1. Protocol Registration

This systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analyses Statement guidelines (PRISMA) [37] and was registered in Figshare [38].

2.2. Study Search and Selection

A literature search was conducted by a specialist. To extract the appropriate literature, the search terms were “sarcopenia,” “muscle atrophy,” “stroke,” “hemorrhagic stroke,” “cerebrovascular disorders,” “brain infarction,” and “ischemic stroke.” The detailed search strategy is shown in Table S1. We searched the literature in six databases: MEDLINE, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, and Ichushi-web (in Japanese). The last date of the literature search was 4 July 2022.
Two independent reviewers conducted the primary screening by reviewing the title and abstract of the articles using the Rayyan application (Qatar Computing Research Institute, Doha, Qatar) [39]. Two independent reviewers categorized the articles as included or excluded. Subsequently, the full text of the included articles was reviewed and a third independent reviewer made the final decision if any disagreements occurred, according to the PRISMA guideline.

2.3. Eligibility Criteria

We included peer-reviewed full-text articles written in English or Japanese between April 2010 and April 2022. We excluded animal models, qualitative studies, case reports, and conference abstracts. We also excluded systematic reviews, but the adequacy of individual articles was verified. We did not exclude any studies based on the age, sex, or region of the study participants.

2.4. Data Extraction

We extracted the study design, number of days from stroke onset to diagnosis of sarcopenia, age, sample size, sex, setting, the number of patients with sarcopenia, and components of sarcopenia diagnosis from the included articles. The number of days from onset to diagnosis of sarcopenia was calculated based on the mean and median values reported by each study.
The primary outcome was a prevalence of sarcopenia. We calculated the estimated prevalences of sarcopenia pre-stroke, within 10 days of onset, and between 10 days and 1 month. We considered this to be the most reasonable and clinically acceptable approach when integrating all included studies, because most of them did not diagnose sarcopenia at a specific time point (e.g., 19.77 ± 7.07 days). We calculated the estimated prevalences of sarcopenia for each period by extracting the sample sizes and the numbers of patients with sarcopenia from all included studies. We drew bubble plots of sarcopenia prevalence with bubble size as the sample size for each study. The secondary outcome was the diagnostic criteria for sarcopenia.

3. Results

The initial literature search identified 1887 studies. Subsequently, 260 duplicate studies were excluded, and 1627 studies were included in the primary screening. We then reviewed the full text of 55 studies to determine whether they were eligible for inclusion. Twenty studies were excluded at this stage because they were not original papers, lacked definitions of sarcopenia, and had no indication of disease prevalence. Finally, 35 studies were included (Figure 1).
A summary of the included studies is shown in Table S2. The study populations ranged in age from approximately 60–80 years, with the exception of one study. Most studies were conducted in Japanese convalescent rehabilitation wards. Twelve studies were conducted in acute care hospitals.
Of the 35 studies, 32 (91.4%) included Asian patients (Table 1), where 26 (81.3%) included Japanese patients. Two studies (5.7%) were European, and one study (2.9%) was conducted in the USA. Of the 32 studies on Asians, 17 used the AWGS or updated AWGS2019 and 7 studies used the EWGSOP or updated EWGSOP2 to diagnose sarcopenia. Five studies used SARC-F to diagnose sarcopenia. Two European studies used the updated EWGSOP2. The study conducted in the USA used four diagnostic criteria: appendicular lean mass/body mass index, EWGSOP, and International Working Group on Sarcopenia.
Figure 2 shows the components of the diagnosis of sarcopenia. Nineteen studies used muscle strength and skeletal muscle mass to diagnose sarcopenia. A full assessment of muscle strength, skeletal muscle mass, and physical performance was performed in five studies. Regarding muscle strength measurements for the diagnosis of sarcopenia, 24 of the 30 studies used grip strength, excluding the five studies that used the SARC-F. One study used the Medical Research Council score as a measure of muscle strength. For muscle mass assessment, 24 studies used bioimpedance analysis, four studies used dual-energy X-ray absorptiometry, and one study used calf circumference. Of the five studies that performed a full assessment, one study performed Short Physical Performance Battery (SPBB), three studies used gait speed, and one study used both SPPB and gait speed to define low physical performance.
The combination of muscle mass and strength was the most used parameter for the diagnosis of sarcopenia, followed by the combination of muscle mass, muscle strength, and physical function.
Of a total of 35 studies, 5 studies that used SARC-F and one study that used 4 diagnostic criteria were excluded.
Figure 3 shows the trajectories of the prevalence of sarcopenia in the pre- and post-stroke periods. Most of the included studies were conducted within 40 days of stroke onset; three studies diagnosed pre-stroke sarcopenia using SARC-F. The estimated prevalences of sarcopenia in pre-stroke, within 10 days, and from 10 days to 1 month after stroke were 15.8%, 29.5%, and 51.6%, respectively. The prevalence of sarcopenia increased approximately 15% from pre-stroke to 10 days after onset, and increased by approximately 20% from 10 days to 1 month after onset.
The bubble size indicates the sample size for the individual studies, and the squares indicate the estimate prevalences of sarcopenia in pre-stroke, within 10 days of onset, and between 10 days and 1 month after stroke, respectively.

4. Discussion

We examined the trajectories of the prevalence of sarcopenia in the pre- and post-stroke periods. This systematic review recorded two major findings. First, 91.4% of the studies on stroke-related sarcopenia were conducted in Asian populations, especially in the Japanese population. Accordingly, AWGS or AWGS2019 was mainly used as the diagnostic criteria. Second, the prevalence of sarcopenia in pre-stroke and stroke patients increased over time, it increased by approximately 15% from pre-stroke to 10 days after onset, and increased by approximately 20% from 10 days to 1 month after onset.
East Asia is aging rapidly, especially Japan, which has the highest aging rate worldwide [40]. Indeed, median age of stroke onset has increased over the past 20 years, and the median age of ischemic stroke onset in women has risen to above the age of 80 years since 2016 [8]. The high rate of the aging population may have led to an increasing number studies on stroke-related sarcopenia in Japan, which have mostly been conducted in convalescent rehabilitation wards [17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32]. Convalescent rehabilitation wards are a unique setting for intensive rehabilitation after the acute phase of stroke [41]. Stroke patients are transferred to convalescent rehabilitation wards approximately 2 weeks after stroke onset when they do not require advanced medical management. Assessing the body composition for sarcopenia is easier during this period because the effects of systemic inflammation, fever, and edema are usually subtle. BIA was used to measure skeletal muscle mass in most of the studies conducted in the convalescent rehabilitation wards. Apart from the non-invasiveness and simplicity of using BIA, the minimal influence of factors inhibiting the measurement of muscle mass may have facilitated the diagnosis of sarcopenia. Combined nutritional management and rehabilitation seems to be an effective intervention for stroke patients with sarcopenia admitted to convalescent rehabilitation wards [42], which may facilitate the assessment of sarcopenia in patients with stroke. In addition, Asian patients with stroke may suffer from sarcopenia due to their small body mass index (BMI) as well as aging. A large discrepancy is observed between the mean BMI of the Asian population, approximately 20 kg/m2, and that of people from the Western countries, as demonstrated by a study conducted in the USA included in this review [43] that shows a mean BMI of approximately 30 kg/m2. Thus, stroke-related sarcopenia may be a concept focused primarily on the Asian population.
AWGS or AWGS2019 was mainly used to diagnose sarcopenia in Asian patients. However, only five studies diagnosed sarcopenia using a full assessment including muscle strength, skeletal muscle mass, and physical performance, and 19 studies diagnosed sarcopenia using only muscle strength and skeletal muscle mass. Assessment of physical performance in stroke patients is difficult due to impaired consciousness and paralysis, which may be the reason only a few studies performed full assessments. However, it is necessary to discuss the need for a full assessment, including physical performance, since skeletal muscle mass and muscle strength are also directly affected by stroke [44,45]. Alternatively, it is crucial to standardize the diagnostic criteria for sarcopenia in conditions where a full assessment is infeasible.
The prevalence of malnutrition, which is closely related to sarcopenia, has been reported to increase over time from the onset of stroke. In a meta-analysis by Huppertz et al., malnutrition in the hyperacute, early subacute, and chronic phases of stroke increased over time to 19%, 52%, and 72%, respectively [46]. The overall prevalence of undernutrition, not just that in patients with stroke, has been reported to be highest in rehabilitation settings [47,48]. Stroke patients develop muscle atrophy [44] and muscle weakness [45] immediately after the onset of the disease. Muscle weakness and skeletal muscle loss due to paralysis and related disuse [49] reduce physical activity, which leads to the onset or increased severity of sarcopenia. A systematic review showed that more than 78% of time is spent in the sedentary state regardless of the time after the onset of stroke [50]. In addition, consciousness and dysphagia cause decreased nutritional intake, which accelerates the loss of muscle mass and muscle weakness. Dysphagia and sarcopenia affect each other. Patients with dysphagia would have more severe sarcopenia compared with those without [19,51]. Many studies have diagnosed sarcopenia using only muscle strength and muscle mass, which may cause overdiagnosis that has led to the increase in the prevalence of sarcopenia over time. A study that followed the trajectory of sarcopenia indicators after hospitalization for 3 months reported that physical performance recovered early after disease onset, whereas muscle strength and skeletal muscle mass did not recover until the time of hospital admission [52]. The results of this systematic review indicate that sarcopenia is mostly diagnosed by muscle strength and skeletal muscle mass in patients with stroke. The results of our systematic review seem reasonable as the prevalence of sarcopenia increased over time after the onset of the disease.
The strength of this systematic review is that it demonstrates that the prevalence of sarcopenia increases over time in patients with stroke. Identifying the trajectory of the prevalence of sarcopenia can provide a basis for intervention to prevent the onset and worsening of sarcopenia. However, our systematic review has some limitations. First, we could not determine the long-term trajectory of sarcopenia because only a few studies investigated the prevalence of sarcopenia 40 days after stroke onset. Future studies are needed to clarify the long-term trajectory of sarcopenia after the onset of stroke. Second, the timing of sarcopenia diagnosis varied among studies, making it difficult to quantitatively integrate prevalence rates. This seemed to depend on the healthcare systems of the countries in which the studies were conducted.

5. Conclusions

This systematic review showed that most studies of sarcopenia in stroke patients have been conducted in Asians, especially Japanese persons. The prevalence of sarcopenia in pre-stroke and stroke patients increased over time. Healthcare providers should be aware that the prevalence of sarcopenia increases during the acute phase of stroke and strive to prevent the onset or worsening of sarcopenia.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu15010113/s1, Table S1: Search strategy for the systematic review; Table S2: Summary of the included studies [53,54,55,56,57,58,59,60,61].

Author Contributions

Conceptualization, T.I., J.U., F.K., H.K., A.N., K.M. (Kenta Murotani), Y.S. and K.M. (Keisuke Maeda); writing—original draft preparation, T.I.; writing—review and editing, T.I., J.U., F.K., H.K., A.N., K.M. (Kenta Murotani), Y.S. and K.M. (Keisuke Maeda); visualization, T.I. All authors have read and agreed to the published version of the manuscript.

Funding

The study was supported by the Japan Society for the Promotion of Science [Grant number: 21H03390 and 22H04923 (CoBiA) to Maeda].

Institutional Review Board Statement

Ethical review and approval were waived for this review because this systematic review was exclusively based on published literature.

Informed Consent Statement

Patients consent was waived for this review because this systematic review was exclusively based on published literature.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Cruz-Jentoft, A.J.; Sayer, A.A. Sarcopenia. Lancet 2019, 393, 2636–2646. [Google Scholar] [CrossRef]
  2. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing 2010, 39, 412–423. [Google Scholar] [CrossRef] [Green Version]
  3. Chen, L.K.; Liu, L.K.; Woo, J.; Assantachai, P.; Auyeung, T.W.; Bahyah, K.S.; Chou, M.Y.; Chen, L.Y.; Hsu, P.S.; Krairit, O.; et al. Sarcopenia in Asia: Consensus report of the Asian working group for sarcopenia. J. Am. Med. Dir. Assoc. 2014, 15, 95–101. [Google Scholar] [CrossRef]
  4. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019, 48, 16–31. [Google Scholar] [CrossRef] [Green Version]
  5. Chen, L.K.; Woo, J.; Assantachai, P.; Auyeung, T.W.; Chou, M.Y.; Iijima, K.; Jang, H.C.; Kang, L.; Kim, M.; Kim, S.; et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J. Am. Med. Dir. Assoc. 2020, 21, 300–307.e2. [Google Scholar] [CrossRef]
  6. Martone, A.M.; Bianchi, L.; Abete, P.; Bellelli, G.; Bo, M.; Cherubini, A.; Di Bari, M.; Maggio, M.; Manca, G.M.; Marzetti, E.; et al. The incidence of sarcopenia among hospitalized older patients: Results from the Glisten study. J. Cachexia. Sarcopenia Muscle 2017, 8, 907–914. [Google Scholar] [CrossRef]
  7. Feigin, V.L.; Nichols, E.; Alam, T.; Bannick, M.S.; Beghi, E.; Blake, N.; Culpepper, W.J.; Dorsey, E.R.; Elbaz, A.; Ellenbogen, R.G.; et al. Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019, 18, 459–480. [Google Scholar] [CrossRef] [Green Version]
  8. Toyoda, K.; Yoshimura, S.; Nakai, M.; Koga, M.; Sasahara, Y.; Sonoda, K.; Kamiyama, K.; Yazawa, Y.; Kawada, S.; Sasaki, M.; et al. Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes. JAMA Neurol. 2022, 79, 61–69. [Google Scholar] [CrossRef]
  9. Sennfält, S.; Norrving, B.; Petersson, J.; Ullberg, T. Long-Term Survival and Function after Stroke: A Longitudinal Observational Study from the Swedish Stroke Register. Stroke 2019, 50, 53–61. [Google Scholar] [CrossRef]
  10. Scherbakov, N.; Sandek, A.; Doehner, W. Stroke-Related Sarcopenia: Specific Characteristics. J. Am. Med. Dir. Assoc. 2015, 16, 272–276. [Google Scholar] [CrossRef]
  11. Scherbakov, N.; Von Haehling, S.; Anker, S.D.; Dirnagl, U.; Doehner, W. Stroke induced Sarcopenia: Muscle wasting and disability after stroke. Int. J. Cardiol. 2013, 170, 89–94. [Google Scholar] [CrossRef] [PubMed]
  12. Sato, Y.; Yoshimura, Y.; Abe, T. Phase Angle as an Indicator of Baseline Nutritional Status and Sarcopenia in Acute Stroke. J. Stroke Cerebrovasc. Dis. 2022, 31, 106220. [Google Scholar] [CrossRef] [PubMed]
  13. Nozoe, M.; Kubo, H.; Kanai, M.; Yamamoto, M.; Okakita, M.; Suzuki, H.; Shimada, S.; Mase, K. Reliability and validity of measuring temporal muscle thickness as the evaluation of sarcopenia risk and the relationship with functional outcome in older patients with acute stroke. Clin. Neurol. Neurosurg. 2021, 201, 106444. [Google Scholar] [CrossRef] [PubMed]
  14. Abe, T.; Yoshimua, Y.; Imai, R.; Sato, Y. A Combined Assessment Method of Phase Angle and Skeletal Muscle Index to Better Predict Functional Recovery after Acute Stroke. J. Nutr. Health Aging 2022, 26, 445–451. [Google Scholar] [CrossRef] [PubMed]
  15. Lee, H.; Lee, I.H.; Heo, J.N.; Baik, M.; Park, H.; Lee, H.S.; Nam, H.S.; Kim, Y.D. Impact of Sarcopenia on Functional Outcomes Among Patients With Mild Acute Ischemic Stroke and Transient Ischemic Attack: A Retrospective Study. Front. Neurol. 2022, 13, 841945. [Google Scholar] [CrossRef] [PubMed]
  16. Bellelli, G.; Zambon, A.; Volpato, S.; Abete, P.; Bianchi, L.; Bo, M.; Cherubini, A.; Corica, F.; Di Bari, M.; Maggio, M.; et al. The association between delirium and sarcopenia in older adult patients admitted to acute geriatrics units: Results from the GLISTEN multicenter observational study. Clin. Nutr. 2018, 37, 1498–1504. [Google Scholar] [CrossRef] [PubMed]
  17. Kanai, M.; Nozoe, M.; Ohtsubo, T.; Yasumoto, I.; Ueno, K. Relationship of Functional Outcome With Sarcopenia and Objectively Measured Physical Activity in Patients With Stroke Undergoing Rehabilitation. J. Aging Phys. Act. 2022, 1–6. [Google Scholar] [CrossRef]
  18. Shimizu, A.; Fujishima, I.; Maeda, K.; Murotani, K.; Ohno, T.; Nomoto, A.; Nagami, S.; Nagano, A.; Sato, K.; Ueshima, J.; et al. Association between food texture levels consumed and the prevalence of malnutrition and sarcopenia in older patients after stroke. Eur. J. Clin. Nutr. 2022, 76, 1576–1582. [Google Scholar] [CrossRef]
  19. Shimizu, A.; Fujishima, I.; Maeda, K.; Murotani, K.; Ohno, T.; Nomoto, A.; Nagami, S.; Nagano, A.; Sato, K.; Ueshima, J.; et al. Delayed Dysphagia May Be Sarcopenic Dysphagia in Patients After Stroke. J. Am. Med. Dir. Assoc. 2021, 22, 2527–2533.e1. [Google Scholar] [CrossRef]
  20. Shiraishi, A.; Yoshimura, Y.; Wakabayashi, H.; Nagano, F.; Bise, T.; Shimazu, S. Improvement in Oral Health Enhances the Recovery of Activities of Daily Living and Dysphagia after Stroke. J. Stroke Cerebrovasc. Dis. 2021, 30, 105961. [Google Scholar] [CrossRef]
  21. Yoshimura, Y.; Wakabayashi, H.; Nagano, F.; Bise, T.; Shimazu, S.; Shiraishi, A. Elevated Creatinine-Based Estimated Glomerular Filtration Rate is Associated with Increased Risk of Sarcopenia, Dysphagia, and Reduced Functional Recovery after Stroke. J. Stroke Cerebrovasc. Dis. 2021, 30, 105491. [Google Scholar] [CrossRef] [PubMed]
  22. Nishioka, S.; Yamanouchi, A.; Matsushita, T.; Nishioka, E.; Mori, N.; Taguchi, S. Validity of calf circumference for estimating skeletal muscle mass for the patients after stroke. Nutrition 2021, 82, 111028. [Google Scholar] [CrossRef] [PubMed]
  23. Yoshimura, Y.; Wakabayashi, H.; Nagano, F.; Bise, T.; Shimazu, S.; Shiraishi, A. Low Hemoglobin Levels are Associated with Sarcopenia, Dysphagia, and Adverse Rehabilitation Outcomes After Stroke. J. Stroke Cerebrovasc. Dis. 2020, 29, 105405. [Google Scholar] [CrossRef] [PubMed]
  24. Nagano, F.; Yoshimura, Y.; Bise, T.; Shimazu, S.; Shiraishi, A. Muscle mass gain is positively associated with functional recovery in patients with sarcopenia after stroke. J. Stroke Cerebrovasc. Dis. 2020, 29, 105017. [Google Scholar] [CrossRef] [PubMed]
  25. Yoshimura, Y.; Wakabayashi, H.; Bise, T.; Nagano, F.; Shimazu, S.; Shiraishi, A.; Yamaga, M.; Koga, H. Sarcopenia is associ-ated with worse recovery of physical function and dysphagia and a lower rate of home discharge in Japanese hospitalized adults undergoing convalescent rehabilitation. Nutrition 2019, 61, 111–118. [Google Scholar] [CrossRef] [PubMed]
  26. Yoshimura, Y.; Wakabayashi, H.; Bise, T.; Tanoue, M. Prevalence of sarcopenia and its association with activities of daily living and dysphagia in convalescent rehabilitation ward inpatients. Clin. Nutr. 2018, 37, 2022–2028. [Google Scholar] [CrossRef]
  27. Shiraishi, A.; Yoshimura, Y.; Wakabayashi, H.; Tsuji, Y. Prevalence of stroke-related sarcopenia and its association with poor oral status in post-acute stroke patients: Implications for oral sarcopenia. Clin. Nutr. 2018, 37, 204–207. [Google Scholar] [CrossRef]
  28. Inoue, T.; Maeda, K.; Shimizu, A.; Nagano, A.; Ueshima, J.; Sato, K.; Murotani, K. Calf circumference value for sarcopenia screening among older adults with stroke. Arch. Gerontol. Geriatr. 2020, 93, 104290. [Google Scholar] [CrossRef]
  29. Matsushita, T.; Nishioka, S.; Taguchi, S.; Yamanouchi, A. Sarcopenia as a predictor of activities of daily living capability in stroke patients undergoing rehabilitation. Geriatr. Gerontol. Int. 2019, 19, 1124–1128. [Google Scholar] [CrossRef]
  30. Tanaka, R.; Yoshimura, Y.; Shimazu, S.; Kitahara, K. Sarcopenia-induced reduction of instrumental activities of daily living among stroke patients discharged to home (Japanese). Sagyoryoho 2021, 40, 730–737. [Google Scholar]
  31. Ito, Y.; Nomura, S.; Yoshimura, Y. Incidence of new-onset sarcopenia and associated factors in stroke patients on a con-valescent rehabilitation ward (Japanese). JSPEN 2021, 3, 28–35. [Google Scholar]
  32. Yoshimura, Y.; Bise, T.; Nagano, F.; Shimazu, S.; Shiraishi, A.; Yamaga, M.; Koga, H. Systemic Inflammation in the Recovery Stage of Stroke: Its Association with Sarcopenia and Poor Functional Rehabilitation Outcomes. Prog. Rehabil. Med. 2018, 3, 20180011. [Google Scholar] [CrossRef] [PubMed]
  33. Nozoe, M.; Kubo, H.; Kanai, M.; Yamamoto, M.; Shimada, S.; Mase, K. Sarcopenia risk and diabetes mellitus are independent factors for lower limb muscle strength in older patients with acute stroke: A cross-sectional study. Nutrition 2021, 84, 111025. [Google Scholar] [CrossRef] [PubMed]
  34. Nozoe, M.; Kanai, M.; Kubo, H.; Yamamoto, M.; Shimada, S.; Mase, K. Prestroke sarcopenia and functional outcomes in elderly patients who have had an acute stroke: A prospective cohort study. Nutrition 2019, 66, 44–47. [Google Scholar] [CrossRef] [PubMed]
  35. Nozoe, M.; Kanai, M.; Kubo, H.; Yamamoto, M.; Shimada, S.; Mase, K. Prestroke Sarcopenia and Stroke Severity in Elderly Patients with Acute Stroke. J. Stroke Cerebrovasc. Dis. 2019, 28, 2228–2231. [Google Scholar] [CrossRef] [PubMed]
  36. Su, Y.; Yuki, M.; Hirayama, K.; Otsuki, M. Development and Internal Validation of a Nomogram to Predict Post-Stroke Fatigue After Discharge. J. Stroke Cerebrovasc. Dis. 2021, 30, 105484. [Google Scholar] [CrossRef]
  37. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The Prisma 2020 statement: An updated guideline for reporting systematic reviews. BMJ Br. Med. J. 2021, 372, n71. [Google Scholar] [CrossRef]
  38. Inoue, T.; Ueshima, J.; Nagano, A.; Kawase, F. Prevalence of sarcopenia through the life course including pre and post stroke. Figshare J. Contrib. 2022. [Google Scholar] [CrossRef]
  39. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst. Rev. 2016, 5, 210. [Google Scholar] [CrossRef] [Green Version]
  40. Population of the Older Adults. Statistics Bureau of Japan. Available online: https://www.stat.go.jp/english/data/jinsui/tsuki/index.html (accessed on 1 November 2022).
  41. Miyai, I.; Sonoda, S.; Nagai, S.; Takayama, Y.; Inoue, Y.; Kakehi, A.; Kurihara, M.; Ishikawa, M. Results of new policies for inpatient rehabilitation coverage in Japan. Neurorehabil. Neural Repair 2011, 25, 540–547. [Google Scholar] [CrossRef]
  42. Yoshimura, Y.; Bise, T.; Shimazu, S.; Tanoue, M.; Tomioka, Y.; Araki, M.; Nishino, T.; Kuzuhara, A.; Takatsuki, F. Effects of a leucine-enriched amino acid supplement on muscle mass, muscle strength, and physical function in post-stroke patients with sarcopenia: A randomized controlled trial. Nutrition 2019, 58, 1–6. [Google Scholar] [CrossRef] [PubMed]
  43. Ryan, A.S.; Ivey, F.M.; Serra, M.C.; Hartstein, J.; Hafer-Macko, C.E. Sarcopenia and Physical Function in Middle-Aged and Older Stroke Survivors. Arch. Phys. Med. Rehabil. 2017, 98, 495–499. [Google Scholar] [CrossRef]
  44. Arasaki, K.; Igarashi, O.; Ichikawa, Y.; Machida, T.; Shirozu, I.; Hyodo, A.; Ushijima, R. Reduction in the motor unit number estimate (MUNE) after cerebral infarction. J. Neurol. Sci. 2006, 250, 27–32. [Google Scholar] [CrossRef] [PubMed]
  45. Harris, M.L.; Polkey, M.I.; Bath, P.M.W.; Moxham, J. Quadriceps muscle weakness following acute hemiplegic stroke. Clin. Rehabil. 2001, 15, 274–281. [Google Scholar] [CrossRef] [PubMed]
  46. Huppertz, V.; Guida, S.; Holdoway, A.; Strilciuc, S.; Baijens, L.; Schols, J.M.G.A.; van Helvoort, A.; Lansink, M.; Muresanu, D.F. Impaired Nutritional Condition After Stroke From the Hyperacute to the Chronic Phase: A Systematic Review and Meta-Analysis. Front. Neurol. 2022, 12, 2459. [Google Scholar] [CrossRef] [PubMed]
  47. Cereda, E.; Pedrolli, C.; Klersy, C.; Bonardi, C.; Quarleri, L.; Cappello, S.; Turri, A.; Rondanelli, M.; Caccialanza, R. Nutritional status in older persons according to healthcare setting: A systematic review and meta-analysis of prevalence data using MNA®. Clin. Nutr. 2016, 35, 1282–1290. [Google Scholar] [CrossRef]
  48. Kaiser, M.J.; Bauer, J.M.; Rämsch, C.; Uter, W.; Guigoz, Y.; Cederholm, T.; Thomas, D.R.; Anthony, P.S.; Charlton, K.E.; Maggio, M.; et al. Frequency of malnutrition in older adults: A multinational perspective using the mini nutritional assessment. J. Am. Geriatr. Soc. 2010, 58, 1734–1738. [Google Scholar] [CrossRef]
  49. Hunnicutt, J.L.; Gregory, C.M. Skeletal muscle changes following stroke: A systematic review and comparison to healthy individuals. Top. Stroke Rehabil. 2017, 24, 463–471. [Google Scholar] [CrossRef]
  50. Fini, N.A.; Holland, A.E.; Keating, J.; Simek, J.; Bernhardt, J. How physically active are people following stroke? Systematic review and quantitative synthesis. Phys. Ther. 2017, 97, 707–717. [Google Scholar] [CrossRef] [Green Version]
  51. Maeda, K.; Akagi, J. Decreased Tongue Pressure is Associated with Sarcopenia and Sarcopenic Dysphagia in the Elderly. Dysphagia 2015, 30, 80–87. [Google Scholar] [CrossRef]
  52. Aarden, J.J.; Reijnierse, E.M.; van der Schaaf, M.; van der Esch, M.; Reichardt, L.A.; van Seben, R.; Bosch, J.A.; Twisk, J.W.R.; Maier, A.B.; Engelbert, R.H.H.; et al. Longitudinal Changes in Muscle Mass, Muscle Strength, and Physical Performance in Acutely Hospitalized Older Adults. J. Am. Med. Dir. Assoc. 2021, 22, 839–845.e1. [Google Scholar] [CrossRef] [PubMed]
  53. Yao, R.; Yao, L.; Yuan, C.; Gao, B.-L. Accuracy of Calf Circumference Measurement, SARC-F Questionnaire, and Ishii’s Score for Screening Stroke-Related Sarcopenia. Front. Neurol. 2022, 13, 880907. [Google Scholar] [CrossRef] [PubMed]
  54. Choi, Y.; Im, S.; Park, G.Y. Ultrasound evaluation of the rectus femoris for sarcopenia in patients with early subacute stroke. J. Clin. Med. 2021, 10, 3010. [Google Scholar] [CrossRef] [PubMed]
  55. Chang, K.V.; Wu, W.T.; Huang, K.C.; Han, D.S. Segmental body composition transitions in stroke patients: Trunks are different from extremities and strokes are as important as hemiparesis. Clin. Nutr. 2020, 39, 1968–1973. [Google Scholar] [CrossRef] [PubMed]
  56. Aydin, T.; Kesikta, F.N.; Oren, M.M.; Erdogan, T.; Ahisha, Y.C.; Kizilkurt, T.; Corum, M.; Karacan, I.; Öztürk, S.; Bahat, G. Sarcopenia in patients following stroke: An overlooked problem. Int. J. Rehabil. Res. 2021, 44, 269–275. [Google Scholar] [CrossRef]
  57. Jang, Y.; Im, S.; Han, Y.; Koo, H.; Sohn, D.; Park, G.Y. Can initial sarcopenia affect poststroke rehabilitation outcome? J. Clin. Neurosci. 2020, 71, 113–118. [Google Scholar] [CrossRef]
  58. Park, S.; Ham, J.O.; Lee, B.K. A positive association between stroke risk and sarcopenia in men aged ≥ 50 years, but not women: Results from the Korean National Health and Nutrition Examination Survey 2008–2010. J. Nutr. Health Aging 2014, 18, 806–812. [Google Scholar] [CrossRef]
  59. Maeda, K.; Akagi, J. Cognitive impairment is independently associated with definitive and possible sarcopenia in hospitalized older adults: The prevalence and impact of comorbidities. Geriatr. Gerontol. Int. 2017, 17, 1048–1056. [Google Scholar] [CrossRef]
  60. Shibazaki, K.; Wakutani, Y.; Takao, Y. Sarcopenia in acute ischemic stroke patients (Japanese). JPN J. Strok. 2021, 43, 409–415. [Google Scholar] [CrossRef]
  61. Tanaka, K.; Tanaka, K.; Kose, T.; Takahashi, M.; Kamasaki, D.; Ota, H. Prevalence and characteristics of sarcopenia in acute stroke patients (Japanese). Rigakuryoho Saga 2021, 7, 21–27. [Google Scholar]
Nutrients 15 00113 g001 550
Figure 1. Article selection flowchart according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses Statement.
Figure 1. Article selection flowchart according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses Statement.
Nutrients 15 00113 g001
Nutrients 15 00113 g002 550
Figure 2. Components of Sarcopenia.
Figure 2. Components of Sarcopenia.
Nutrients 15 00113 g002
Nutrients 15 00113 g003 550
Figure 3. Trajectories of prevalence of sarcopenia in pre- and post-onset period in patients with stroke.
Figure 3. Trajectories of prevalence of sarcopenia in pre- and post-onset period in patients with stroke.
Nutrients 15 00113 g003
Table
Table 1. Diagnostic criteria or screening tool for sarcopenia according to race.
Table 1. Diagnostic criteria or screening tool for sarcopenia according to race.
Diagnostic Criteria
(Screening Tool)		Study Region, Number of Studies
Asia, n = 32Europe, n = 2
AWGS or AWGS2019170
EWGSOP 272
SARC-F50
FNIH10
Others20
One study that calculated sarcopenia prevalence using multiple diagnostic criteria was excluded from this table. Abbreviations: AWGS, Asian Working Group for Sarcopenia; EWGSOP, European Working Group on Sarcopenia in Older People; FNIH, Foundation for the National Institutes of Health.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Inoue, T.; Ueshima, J.; Kawase, F.; Kobayashi, H.; Nagano, A.; Murotani, K.; Saino, Y.; Maeda, K. Trajectories of the Prevalence of Sarcopenia in the Pre- and Post-Stroke Periods: A Systematic Review. Nutrients 2023, 15, 113. https://doi.org/10.3390/nu15010113

AMA Style

Inoue T, Ueshima J, Kawase F, Kobayashi H, Nagano A, Murotani K, Saino Y, Maeda K. Trajectories of the Prevalence of Sarcopenia in the Pre- and Post-Stroke Periods: A Systematic Review. Nutrients. 2023; 15(1):113. https://doi.org/10.3390/nu15010113

Chicago/Turabian Style

Inoue, Tatsuro, Junko Ueshima, Fumiya Kawase, Haruko Kobayashi, Ayano Nagano, Kenta Murotani, Yoko Saino, and Keisuke Maeda. 2023. "Trajectories of the Prevalence of Sarcopenia in the Pre- and Post-Stroke Periods: A Systematic Review" Nutrients 15, no. 1: 113. https://doi.org/10.3390/nu15010113

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop